Defining Patient Populations for the Next Wave of IBD Treatments – The Janssen Approach

Time: 4:00 pm
day: Day One


  • Where are we going and where are we today? From all comer populations to targeting differentiated patient populations – which role do molecular markers play and in which programs could they be critical?
  • Combination therapy development in IBD is behind other areas in medicine (e.g. HIV, hepatitis, oncology) – could molecular phenotyping help to advance these complex development programs in IBD?